<DOC>
	<DOCNO>NCT00427934</DOCNO>
	<brief_summary>The purpose study evaluate whether maraviroc , investigational drug give methotrexate ( MTX ) safe effective treatment rheumatoid arthritis adult patient .</brief_summary>
	<brief_title>Maraviroc Rheumatoid Arthritis</brief_title>
	<detailed_description>Following plan interim analysis POC component 21 August 2008 internal DMC ( Data Monitoring Committee ) study A4001056 , trial discontinue due lack efficacy . All participate investigators/country office monitor notify 22 August 2008 cease patient enrollment . The DMC indicate maraviroc well tolerate Rheumatoid Arthritis patient safety concern study . The termination date trial 07 October 2008 last patient last visit occur .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Must legal age consent Must active rheumatoid arthritis base upon American College Rheumatology ( ACR ) 1987 ( Revised Criteria ) ; minimum disease criterion require entry efficacy component study Must meet ACR 1991 Revised Criteria Global Functional Status RA , Class I , II , III Must receive methotrexate least 12 week duration stable dose 4 week . Diagnosed inflammatory arthritis secondary noninflammatory arthritis would interfere disease activity assessment . Subject receive prior treatment certain medication rheumatoid arthritis Tuberculosis and/or positive tuberculin reaction Significant trauma major surgery within 2 month History alcohol and/or drug abuse outside defined period abstinence History find screen postural hypotension Any condition would affect oral absorption drug History cancer remission le 3 year Grade IIIIV congestive heart failure Having infection human immunodeficiency virus ( HIV ) , Hepatitis B C evidence active infection Abnormalities clinical laboratory assessment complete screen visit elevate liver enzymes , decrease hemoglobin abnormal ECG Having positive chemokine receptor 5 ( CCR5 ) delta 32 mutation Requiring use certain medication Lactating pregnant woman subject reproductive potential unwilling use adequate method birth control Chronic recent serious lifethreatening infection ; severe , progressive and/or uncontrollable renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological disease within 12 week first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>